IMR Press / EJGO / Volume 23 / Issue 6 / pii/2002216

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Evaluation of the circulating fraction of the HER-2/neu oncogene in patients with cervical cancer

Show Less
1 Department of Obstetrics and Gynecology, Texas Tech Health Science Center, Lubbock, TX (USA)
2 Department of Medicine, Texas Tech Health Science Center, Lubbock, TX (USA)
Eur. J. Gynaecol. Oncol. 2002, 23(6), 491–495;
Published: 10 December 2002

Objective: To evaluate circulating HER-2/neu in cervical cancer patients prior to and following treatment. Methods: Controls, and patients with either cervical dysplasia or cancer taken from an active gynecologic oncology service were evaluated for the expression of HER-2/neu in serum by ELISA before and following surgery, radiation, chemotherapy or combina­tions thereof. The resulant data was then evaluated for significance by either ANOVA or non-parametric testing. Results: Mean differences were noted for patients with cervical cancer compared to controls. Patients with a good response to the chemotherapy indicated an increase in the serum oncogene, while those not responding either had no marked change or decreased the level of serum HER-2/neu. Conclusions: As serum HER-2/neu is a membrane bound portion of the intact molecule, these results suggest that due to the induction of cell death and breakdown, the liberation of this fraction (increased levels in the serum), is a viable indicator of response to treatment in some patients. A more detailed examination of this possibility along with expanded correlation with tissue expression is required.

Cervical cancer
Back to top